Dihydroergocornine is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity. Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects.
- Mechanism
- Curator reviewed · 3 references
The mechanism of action by which dihydroergocornine exerts its effects are not entirely defined. However, it is reported that dihydroergocornine has central and peripheral effects. The fall in blood pressure seems to be related to the stimulation of the vasodilator center. It has been demonstrated that dihydroergocornine possesses potent adrenolytic and sympathicolytic actions. The effect of dihydroergocornine is related to the inhibitory effect against the serotonin and noradrenaline receptors in which dihydroergocornine seems to be very potent against a stimulation-induced noradrenaline overflow. It also presents a stimulatory effect in arterial and venous smooth muscle when administered at slightly higher concentrations than the necessary for the inhibitory effect.
- Primary indication
- To know more about the approved indications please visit DB01049Curator reviewed · 1 structured indication
- Formula / weight
- C31H41N5O5 · 563.699 g/mol (avg)
- First approval
- United States, 1980
Resolves to
SEALOBQTUQIVGU-QNIJNHAOSA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)CWhat you can answer from here — as of September 23, 2026
Which other approved drugs treat the same conditions as Dihydroergocornine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account